## Disruptive Forces in US Healthcare

#### Capturing the Digital Opportunity

Pharmaceutical Information Systems Association July 24, 2013

CONFIDENTIAL AND PROPRIETARY Any use of this material without specific permission of McKinsey & Company is strictly prohibited

McKinsey&Company

GO



Sastry Chilukuri Partner, McKinsey & Company

- Strategy, technology and operations for Pharma, Med Device and Government
- 6 yrs with GE Healthcare in various roles
- BS, Indian Institute of Technology (IIT); MBA, Kellogg



Rena Rosenberg Partner, McKinsey & Company

- Branded and Generic Pharmaceuticals
- Digital Marketing and Sales
- PhD, Economics, University of Chicago

## Disruptive forces shaping the US Healthcare industry

Capturing the Digital Opportunity

## The current landscape represents unprecedented shifts across the industry



#### PROVIDERS Providers are struggling to maintain future profitability with declining reimbursement

2016 2019

ast Modified 3/18/2014 11:48 AM Eastern Standard Time

Printed 3/18/2014 11:50 AM Eastern Standard Time

![](_page_4_Figure_2.jpeg)

1 3248 US acute care hospitals modeled in Objective Health; assumes all states expand Medicare and hospitals do not make changes to cost or revenue 2 Median determined by margin at 50% of hospital market revenue

SOURCE: Objective Health Outside in Reform Impact estimates; CMS Cost Reports 2010

#### PROVIDERS Six strategic priorities for providers

![](_page_5_Picture_1.jpeg)

Implement **broad-ranging cost control programs**, ("Medicare margin" efforts)

![](_page_5_Picture_3.jpeg)

Build sufficient **scale in core hospital operations** (through in-region M&A or outsourcing), and expand across the continuum of care

![](_page_5_Picture_5.jpeg)

Drive **physician alignment** to support efficiency and quality improvements and improve care coordination

![](_page_5_Picture_7.jpeg)

Explore the full range of **innovative reimbursement models** (including episode-based payments, ACOs or even IDNs)

![](_page_5_Picture_9.jpeg)

Create a **distinctive capability in infrastructure** that addresses value over volume (e.g., EHR & IT infrastructure to allow for data exchange)

![](_page_5_Picture_11.jpeg)

Strengthen **retail capabilities**, including more sophisticated value-based pricing, direct-to-consumer and direct-to-employer supplemental care products

## CHANNEL **New types and combinations of intermediaries are emerging**

![](_page_6_Picture_1.jpeg)

#### CHANNEL Intermediaries – strategic priorities

#### **PBMs**

![](_page_7_Picture_2.jpeg)

**Differentiating on cost** by offering narrow formularies and more aggressive product management

#### Retailers

![](_page_7_Picture_5.jpeg)

Playing in specialty (Walgreens / ABC)

![](_page_7_Picture_7.jpeg)

![](_page_7_Picture_8.jpeg)

**Globalization** (e.g., Amerisource Bergen / Alliance Boots)

![](_page_7_Picture_10.jpeg)

Scaling mid-size players to be more competitive (e.g., Catamaran)

![](_page_7_Picture_12.jpeg)

Increasing involvement in adherence / outcomes (CVS Pharmacy Advisor)

![](_page_7_Picture_14.jpeg)

New value added services / solutions for providers, payors, manufacturers

Value chain migration

(e.g., Medline)

![](_page_7_Picture_16.jpeg)

Involvement in delivering outcomes

![](_page_7_Picture_18.jpeg)

Providing care or collaborating with providers CVS Minute Clinic: Walgreens activity in vaccines)

![](_page_7_Picture_20.jpeg)

Investing in specialty to differentiate and arow

![](_page_7_Picture_22.jpeg)

Negotiating on rebates / COGs, to preserve shrinking **EBIT** margins

![](_page_7_Picture_24.jpeg)

New approaches to and emphasis on private label (front-store excellence in WAGS/Alliance Boots)

![](_page_7_Picture_26.jpeg)

(drugstore.com and

![](_page_7_Picture_28.jpeg)

Strategic redirection (e.g., Celesio)

![](_page_7_Picture_30.jpeg)

New sites of care (e.g., McKesson and DSSI. Cardinal and AssuraMed)

#### PAYERS Key changes to payor market resulting from healthcare reform

| Consumer-<br>driven market      | <ul> <li>By 2016, ~40% of lives in plans actively chosen by consumers</li> <li>Individual market 60-70% low/middle income consumers (&lt;400% FPL)</li> <li>Employer market increasingly consumer choice-driven (e.g., defined contribution private exchanges)</li> </ul>     |
|---------------------------------|---|
| Key<br>consumer<br>insights     | <ul> <li>Brand and price matter</li> <li>Majority say they will trade off provider access to optimize price</li> </ul>  |
| New<br>distribution<br>channels | <ul> <li>Many first time buyers likely to seek multiple channels and consultative support</li> <li>Alternative channels (vs. broker, telesales) expected to grow</li> </ul>   |
| Changing<br>economics           | <ul> <li>Health plans expect operating margins at 2%-5% similar to government programs</li> <li>Risk adjustment rules (3R's) will influence economics – e.g., relative value of compliant, chronically ill patients more valuable than relatively healthy patients</li> </ul> |
| New<br>bases of<br>competition  | <ul> <li>Competition largely by state and local market</li> <li>Increasingly consolidated marketplace with significant new entrants (e.g., in managed Medicaid)</li> </ul>  |

#### PAYERS Five strategic priorities for payors

Reduce traditional medical and admin costs to compete in more pricesensitive world

## Further drive down cost ("bend the trend") through innovative "re-found" health care value approaches, e.g.,

- Develop narrow networks and new care / payment models
- Manage high-risk patients with improved care management

#### Shift to a consumer-centric business model and organization

- Evolve offerings to compete in consumer-driven markets
  - Attract profitable high-risk patients
  - Build capabilities in consumer insights and marketing
  - Develop new pricing approaches to replace traditional underwriting
- Develop consumer-facing and care management capabilities to win in the growing government (Medicare and Medicaid) segment

#### Determine which businesses / markets to play in

5

2

3

**Prepare for new competitors** entering the market (e.g., Medicaid pure plays, providers, other smaller players)

#### PATIENTS What is the impact on patients? Many more (confusing) choices ...

![](_page_10_Figure_1.jpeg)

1 Includes Medicare (FFS, MA), traditional health plan, medicaid 2 Includes individual coverage, MA-PDP

## PATIENTS ... and a digital reaction

![](_page_11_Figure_1.jpeg)

## Implications vary across portfolio – US pharma access environment diverging

| TA categories                            | Access environment  | Primary care examples  | Specialty care examples                |
|--|---|--|--|
| Generics<br>available                    | <ul> <li>Payer control is tightening</li> <li>In some cases,</li> </ul> | Hypertension<br>Cholesterol55% of<br>spend>90% discounts<br>up to 70+% rebates |  |
| No generics<br>but highly                | net prices are<br>falling   | Insulin<br>DPP4s<br>SABAs<br><b>30% of</b><br><b>spend</b>                     | Human<br>growth<br>hormone             |
| SUDSTITUTADIE                            |   | Up to 60+% rebates   | Up to 50+% rebates                     |
|  |   |  | MS (ini's)                             |
| Hard to<br>substitute<br>once patient is | <ul> <li>Limited payer</li> <li>control</li> <li>Prices are</li> </ul>  | Combo ICS/<br>LABAs for<br>asthma  | Anti-TNFs<br>Hemophilia<br>Infertility |
| on treatment                             | increasing rapidly (up to double digit                                  | Up to 20% rebates  | Up to 10% rebates                      |
|  | YoY growth) and   |  | Ornhan tye                             |
| Highly<br>challenging to                 | nowhere close to<br>keeping up with the                                 | Anti-clotting 7% of spend  | HIV 25% of<br>Most of Onc spend        |
| substitute                               | price increase  | 0-1% rebates   | 0-1% rebates                           |

#### What does this all mean?

#### More healthcare spending

Increased healthcare consumption, and potentially in new outlets

#### Greater value orientation

Governments, payors, consumers, and employers will all seek greater value

#### Margin squeeze

Margin pressures mean players must evolve and differentiate on value

#### **Confused consumers**

Consumers changing coverage face complicated healthcare landscape

#### What role will technology play in all this disruption?

#### Contents

- Disruptive forces shaping the US Healthcare industry
- Capturing the Digital opportunity

## There are six main drivers of digital transformation for Pharmaceutical companies

![](_page_15_Figure_1.jpeg)

Last Modified 3/18/2014 11:48 AM Eastern Standard Time Printed 3/-

Source: McKinsey

#### Need for a top-down technology enabled strategy

![](_page_16_Figure_1.jpeg)

McKinsey & Company | 16

#### CAPTURING THE VALUE

## Ensuring business impact from advanced analytics requires covering the five bases

![](_page_17_Figure_2.jpeg)

# Last Modified 3/18/2014 11:48 AM Eastern Standard Time

#### CAPTURING THE VALUE

#### Traditionally unstructured data sources are yielding more insights

| • Social media data<br>(e.g., leading<br>consumer<br>complaints)   | <ul> <li>EMR / EHR<br/>data (e.g.,<br/>relapse rates,<br/>comorbidities)</li> </ul> | <ul> <li>Supply chain<br/>data (e.g.,<br/>months on hand,</li> </ul>                                       |
|--|---|--|
| <ul> <li>Search engine data<br/>(e.g., search terms<br/>pairings as a proxy<br/>for adverse events)</li> <li>Genomics</li> </ul> | <ul> <li>Lab test data</li> </ul>   | <ul> <li>stock-out rates)</li> <li>PV data (e.g., adverse events)</li> <li>Claims registry data</li> </ul> |
| Google"<br>Knome   | Ecorety Corporation of America  | <b>TRUVEN</b><br>HEALTH ANALYTICS  |
|  | pairings as a proxy<br>for adverse events)<br>Genomics<br>Google<br>Google          | pairings as a proxy<br>for adverse events)<br>Genomics<br>Google<br>Google<br>Cicknone                     |

Pharmacos are better able to integrate data sources due to increased insights from unstructured data, easier access to unstructured data, and advanced capabilities to capture value in structured data CAPTURING THE VALUE

#### Multiple stages along the journey – Telco Example

![](_page_19_Figure_2.jpeg)

McKinsey & Company | 19

Last Modified 3/18/2014 11:48 AM Eastern Standard Time

#### CAPTURING THE VALUE

## Example – Pharmacos need to integrate internal and external data sources to execute Big Data opportunities

![](_page_20_Figure_2.jpeg)

\_ast Modified 3/18/2014 11:48 AM Eastern Standard Time

Printed 3/18/2014 11:50 AM Eastern Standard

Time

#### EMERGING DATA TECHNOLOGIES AND PLATFORMS

## Lots of confusion and misunderstanding about emerging data technologies and platforms

![](_page_21_Figure_2.jpeg)

#### EMERGING DATA TECHNOLOGIES AND PLATFORMS

**Example "reference architecture"** 

![](_page_22_Figure_2.jpeg)

McKinsey & Company | 22

GOVERNANCE

#### Data governance is becoming increasingly centralized

#### Examples from "data-driven" industry leaders

**Dedicated** Mix of business and "The new leader was 100% dedicated to leader technology mindset, vision data and analytics, and was able to engage of where data can drive in business-terms and translate under competitive advantage the covers into technology moves." **Demand-**"... deep understanding of business drivers Business perspective on driven where data can drive profitand economics created an heat map of driving decisions where data could make a real difference." Global, centralized BI Orq "We had one group across the globe to enablement group responsible for manage all our system instrumentation insights, engineering, and and data warehousing needs. They also built our tools and led advanced analytics." demand planning **Talent** "The BI team was full of PhDs and Specialists of predictive analytics, machine learning, 'super-brains'. These guys were at data visualization skills the cutting-edge."

#### GOVERNANCE

#### Many organizations have created leadership positions focused on data and insights

![](_page_24_Picture_2.jpeg)

Sally Hinds

- Reuters Enterprise Platform for Data Management (TREP DM) business line. Prior to this role:
  - HSBC, head of global market data team, Global Head of Enterprise Data Mgmt.
  - Credit Suisse, program manager on reference data management

#### Opportunity now to evolve the pharma commercial model

![](_page_25_Figure_1.jpeg)

## Digital customer engagement is an example of how big data insights can be used to create impact

ILLUSTRATIVE

![](_page_26_Figure_2.jpeg)

## Kaiser Permanente has used integrated software and data solutions to improve services and outcomes

![](_page_27_Picture_1.jpeg)

- Using advanced analytics of members to design tailored services
- Quantifies the member's risk of serious conditions (e.g., heart attack, stroke, cancer, onset and complications of diabetes),
- Prioritizes actions the member can take to reduce their risk based on their preferences
- Activates the patient and improves adherence
- Used for innovative disease modelling

### Meaningful impact on risk and adherence

![](_page_27_Figure_8.jpeg)

IndiGO™ (Individualized Guidelines and Outcomes) is intended solely for informational purposes only. It is not intended to replace or otherwise serve as advice from a medical professional. If you have any questions about the information or results presented, seek assistance from your medical professional.

## A pharmaco's customer transformation journey depends on your starting point and the organization's ambition

![](_page_28_Figure_1.jpeg)

Level of ambition depends on how broadly you wish to scale

#### **3** Leading practices for building a "Digital Enterprise"

| Traditional transformation |   | 'Digital' transformation   |
|----------------------------|---|--|
| Approach                   | Conduct analysis; identify and size the opportunity                       | ACTION FIRST – Embed strong bias to action and operational orientation to capture impact                       |
| Analytics                  | Analysis based on looking at only<br>a limited set of<br>information      | <b>DATA IMMERSION</b> – Attain full data access to enable holistic analytics and capability building           |
| End-<br>products           | Application of tried and true tools<br>and frameworks to deliver insights | <b>INTERACTIVE TOOLS</b> – Bring insights to life through interactive, digital end products to change behavior |
| Scaling                    | Milestones including traditional progress reviews and workshops           | FULL IMPLEMENTATION – Scale<br>solutions and create organizational<br>stickiness and maximum impact            |
| Agenda                     | 2-3 Strategy Agenda or Functional areas                                   | ACROSS VALUE CHAIN – Apply deep<br>analytics and functional expertise<br>across the value chain                |

## 3 Driving a successful digital enterprise is fundamentally different from typical 'IT' business transformations

![](_page_30_Figure_1.jpeg)

Source: McKinsey

## 3 Redesigning and digitizing key processes underpins : banking examples

| Example | AIB Allied Irish Bank  | <b>XX RBS</b> Group  |  |  |
|---------|--|--|--|--|
|         | <ul> <li>End-to-end redesign and digitization<br/>of the mortgage application process:         <ul> <li>From-scratch design of a new "end-<br/>to-end" process</li> <li>Reiterations/improvement of the<br/>manual process in the work cell</li> <li>Agile development of the IT solution<br/>(iPad), successive versions<br/>immediately tested on staff and<br/>customers, and improved</li> </ul> </li> </ul> | <ul> <li>Digital optimization of relationship initiation process:         <ul> <li>Application of end-to-end digital optimization techniques: reducing the number of documents, simplifying flows, etc.</li> <li>Definition of new performance indicators and dashboard</li> </ul> </li> </ul> |  |  |
| Impact  | <ul> <li>Processing time for applications 15 min</li> <li>service take-up rate, showing very high satisfaction among pilot customers</li> <li>loan applications are fully handled by the program</li> <li>cost reduction</li> </ul>  | <ul> <li>30% - 50% capacity freed up in the teams concerned</li> <li>50% reduction in conversion times</li> <li>Visibility achieved throughout the operational chain, with indicators, directly usable for strategic control</li> </ul>  |  |  |
|         | Which core pharma<br>processes could benefit?  |  |  |  |

Source: McKinsey

## P&G harnesses large and real-time data for technologically enabled decision making

## Context: P&G utilise real-time/ continuous data in their daily decision making

![](_page_32_Picture_2.jpeg)

The "Business Sphere" (high-tech conference room)

"All of this comes with our strategy of being the most digitally enabled company in the world"

Robert McDonald, former CEO

#### What's the innovation

- Every employee has a 'cockpit interface' on their computer – important metrics are tracked real time and they-re alerted to respond/ make decisions when go out of tolerance range
- Weekly meetings (virtual and physical) with leadership team around the world to make business decisions harnessing real-time and continuous data

#### IBM's 'Beehive' enables employees to network in an interactive format

![](_page_33_Picture_1.jpeg)

- "Status update" and "about me" feature allows personalization of content
- Top 5 lists (hive fives) allow users to outline ideas and invite colleague comment
- Event pages publicize and create buzz around upcoming events
- Users rise in status when networks are deeper and wider

"Beyond the desire to share with colleagues on a personal level, we also found Beehive was used to network with those who can assist in career goals within IBM"

SOURCE: DiMicco, J.M; Millen, D.R; Geyer, W; Dugan, C; "Research on the use of Social Software in the Workplace," 2008; Geyer, W; "Beehive-Social Networking inside IBM," 2007

#### How some leading pharmacos have started their journeys

- Top level commitment
- Investing in data, analytics and digital
- Actively shape the immature ecosystem (e.g., data vendors, tech companies)
- Building capabilities around next-gen infrastructure (i.e. cloud)
- Developing new measures of economic impact and measures of success
- Aggressively pursuing talent
- Launching change management programs to educate and convert brand teams, TA heads, researchers and senior management

![](_page_34_Picture_8.jpeg)

#### **Thought-starter questions**

- What changes in the Healthcare ecosystem most impact your business?
- What are your areas of strategic focus?
- What is your innovation agenda partnerships/ new offerings?
- What steps have you taken to build flexibility and agility into your platforms?